Abraham Bassan
Director/Board Member chez CARGO THERAPEUTICS, INC.
Fortune : - $ au 29/02/2024
Profil
Founder of Aurora Medical Group, Inc., Abraham Bassan is Principal at Samsara Biocapital LLC.
Mr. Bassan is also on the board of Vedere Bio II, Inc., Cargo Therapeutics, Inc. and Septerna, Inc.
In the past Mr. Bassan held the position of Associate Director-Program Development at bluebird bio, Inc., Associate for Third Rock Ventures LLC, Director-Program Biology at Revolution Medicines, Inc. and Chief Executive Officer at Aurora Medical Group, Inc.
He received an undergraduate degree from Princeton University and a graduate degree from Stanford University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
-.--% | 19/07/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Postes actifs de Abraham Bassan
Sociétés | Poste | Début |
---|---|---|
CARGO THERAPEUTICS, INC. | Director/Board Member | 01/02/2021 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Director/Board Member | 01/04/2021 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Director/Board Member | 01/11/2021 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/07/2017 |
Anciens postes connus de Abraham Bassan
Sociétés | Poste | Fin |
---|---|---|
REVOLUTION MEDICINES, INC. | Corporate Officer/Principal | 01/07/2017 |
Aurora Medical Group, Inc. | Chief Executive Officer | 01/09/2014 |
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/08/2012 |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Corporate Officer/Principal | 01/05/2010 |
LENZ THERAPEUTICS, INC. | Director/Board Member | - |
Formation de Abraham Bassan
Stanford University | Graduate Degree |
Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
REVOLUTION MEDICINES, INC. | Health Technology |
CARGO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Aurora Medical Group, Inc. | |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Graphite Bio, Inc.
Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |